New drug cocktail shows promise in tough lung cancer

NCT ID NCT04631029

Completed Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated Jun 09, 2026 · Updated 33 times

Summary

This early-phase trial tested a new combination of drugs for people with extensive-stage small cell lung cancer that had not been treated before. The goal was to find the best dose and see if adding entinostat to standard treatments (atezolizumab, carboplatin, and etoposide) is safe and might work better. Only 3 people took part, and the study focused on side effects and how many could complete at least 3 cycles of treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC MALIGNANT NEOPLASM IN THE BRAIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Huntsman Cancer Institute/University of Utah

Salt Lake City, Utah, 84112, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
University of Pittsburgh Cancer Institute (UPCI)

Pittsburgh, Pennsylvania, 15232, United States
University of Virginia Cancer Center

Charlottesville, Virginia, 22908, United States
University of Wisconsin Carbone Cancer Center

Madison, Wisconsin, 53792, United States

Conditions

Explore the condition pages connected to this study.

EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA MALIGNANT SOLID NEOPLASM METASTATIC MALIGNANT NEOPLASM IN THE BRAIN